INVESTORS & MEDIA

INVESTORS
& MEDIA

Events & Presentations

ARCHIVED EVENTS

Date	Event Details
Summary Toggle Jun 15 Jun 15, 2019	European Hematology Association (EHA) 2019 Annual Meeting Supporting Materials REGN1979 in patients with R/R B-NHL 787.6 KB
Summary Toggle Jun 14 10:30 AM EDT Jun 14, 2019 \| 10:30 AM EDT	2019 Annual Meeting of Shareholders listen to webcast Supporting Materials Regeneron 2019 Annual Meeting of Shareholders 2.1 MB
Summary Toggle Jun 11 9:20 AM PDT Jun 11, 2019 \| 9:20 AM PDT	Goldman Sachs Global Healthcare Conference listen to webcast Supporting Materials Regeneron Corporate Presentation June - 2019 1.6 MB
Summary Toggle Jun 1 1:15 PM CDT Jun 1, 2019 \| 1:15 PM CDT	American Society of Clinical Oncology (ASCO) 2019 Annual Meeting Supporting Materials Phase 2 Cemiplimab in locally advanced CSCC – primary analysis 2 MB Phase 1 of REGN3767 (LAG-3) and Cemiplimab 2.3 MB Phase 2 Cemiplimab in metastatic CSCC – 12-month follow-up 348.4 KB
Summary Toggle May 20 10:00 AM EDT May 20, 2019 \| 10:00 AM EDT	UBS Global Healthcare Conference listen to webcast
Summary Toggle May 17 11:00 AM EDT May 17, 2019 \| 11:00 AM EDT	Barclays Biopharmaceuticals CEO/CFO Conference Call Series listen to webcast
Summary Toggle May 15 8:00 AM PDT May 15, 2019 \| 8:00 AM PDT	Bank of America Merrill Lynch Healthcare Conference listen to webcast
Summary Toggle May 15 May 15, 2019	Regeneron Corporate Presentation Supporting Materials Regeneron Corporate Presentation May 2019 1.6 MB
Summary Toggle May 7 8:30 AM EDT May 7, 2019 \| 8:30 AM EDT	Regeneron Pharmaceuticals Q1 2019 Earnings Conference Call listen to webcast
Summary Toggle Mar 15 1:00 PM EDT Mar 15, 2019 \| 1:00 PM EDT	J.P. Morgan 2019 Spring Biotech Conference Call Series Listen to webcast
Summary Toggle Mar 11 11:20 AM EDT Mar 11, 2019 \| 11:20 AM EDT	Cowen 39th Annual Healthcare Conference Listen to webcast Supporting Materials View Presentation 1.6 MB
Summary Toggle Mar 1 Mar 1, 2019	ASCO-SITC 2019 Supporting Materials Phase 1 Cemiplimab NSCLC Monotherapy 348.5 KB Phase 1 Cemiplimab Japanese Patients 358.5 KB Phase 1 TPS Cemiplimab and REGN3767 (LAG-3) 1.5 MB
Summary Toggle Feb 25 Feb 25, 2019	2019 AAAAI Annual Meeting Supporting Materials Phase 3 SINUS-52 Study poster 679.8 KB Phase 3 SINUS-24 Study presentation 531 KB
Summary Toggle Feb 13 Feb 13, 2019	Regeneron Corporate Presentation Supporting Materials Regeneron Corporate Presentation February 2019 1.7 MB
Summary Toggle Feb 9 Feb 9, 2019	Angiogenesis, Exudation, and Degeneration 2019 Supporting Materials Phase 3 PANORAMA 52 Week Data 20.6 MB
Summary Toggle Feb 6 8:30 AM EST Feb 6, 2019 \| 8:30 AM EST	Regeneron Pharmaceuticals Q4 2018 Earnings Conference Call Listen to webcast
Summary Toggle Jan 7 10:30 AM PST Jan 7, 2019 \| 10:30 AM PST	37th Annual J.P. Morgan Healthcare Conference Supporting Materials JP Morgan 2019 1.7 MB Financial Overview 2019 505.7 KB Financial Overview 2018 1.8 MB 2018 Cemiplimab Illustrative Example 35.7 KB Financial Overview 2017 608.5 KB Financial Overview 2016 1 MB Financial Overview 2015 897 KB
Summary Toggle Dec 1 Dec 1, 2018	ASH 2018 Supporting Materials View Presentation 789.4 KB View Presentation 231.7 KB
Summary Toggle Jul 24 12:00 AM EDT Jul 24, 2018 \| 12:00 AM EDT	ASRS 2018 Supporting Materials Phase 3 Panorama 24 Week Data - Wykoff 6.1 MB Outcomes of Anti-VEGF for AMD in Clinical Practice - Moshfeghi 870.7 KB Outcomes in DME w DPP-4 Inhibotors in VISTA and VIVID Trials - Rahimy 440.5 KB Outcomes of AMD CNV VIEW Studies - Do 448.9 KB Outcomes of Anti-VEGF for DME in Clinical Practice - Pitcher 823.3 KB Phase 2 RUBY Trial - Heier 4.6 MB

Investor Relations
914.847.7741
invest@regeneron.com

Media Relations
media@regeneron.com

Investor email alerts

Add Files

2018 Responsibility Report 8.5 MB
Add Files

2018 Annual Report 3.7 MB
Add Files

2019 Proxy Statement 8.2 MB
Add Files

2018 Form 10-K 2.7 MB
Add Files

Senior Management Biographies 3.9 MB
Add Files

Corporate Fact Sheet 2 MB
Add Files

Regeneron Genetics Center Backgrounder 1.8 MB

Investor Relations
914.847.7741
invest@regeneron.com

Media Relations
media@regeneron.com

Investor email alerts